Table 1.
Descriptive statistics for men diagnosed with metastatic prostate cancer between 2005 and 2007 (N = 2,708)
| N | % | |
|---|---|---|
| Race/Ethnicity |
|
|
| White non-Hispanic |
2096 |
77.4 |
| African American non-Hispanic |
326 |
12.0 |
| Hispanic |
159 |
5.9 |
| Other |
127 |
4.7 |
| Age |
|
|
| 66-69 |
375 |
13.9 |
| 70-74 |
499 |
18.4 |
| 75-79 |
555 |
20.5 |
| 80-84 |
645 |
23.8 |
| 85+ |
634 |
23.4 |
| Married |
1583 |
62.3 |
| Urban location |
2396 |
88.5 |
| High PSA at baseline |
2298 |
84.9 |
| Poorly differentiated tumor |
1638 |
60.5 |
| Charlson Comorbidity Index |
|
|
| Zero |
1453 |
53.7 |
| One |
547 |
20.2 |
| Two or higher |
470 |
17.4 |
| Missing |
238 |
8.8 |
| National Cancer Institute (NCI) Combined Index |
|
|
| Zero |
1459 |
54.2 |
| 0-2 |
943 |
35.0 |
| > = 2 |
53 |
2.0 |
| Missing |
238 |
8.8 |
| Bone metastasis |
|
|
| Bone metastasis diagnosis |
|
|
| SEER registry |
1694 |
62.6 |
| Bone metastasis – related utilization |
|
|
| Claims – BM Concurrent, Approach 1 |
1481 |
54.7 |
| Claims – BM Concurrent, Approach 2 |
1363 |
50.3 |
| Claims – BM Concurrent, Approach 3 | 1198 | 44.2 |